Oslo, Norway (19th June 2018) – In conjunction with the hiring of the new Senior Vice President Global Sales & Marketing in NattoPharma and based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May 30th, 2018, the Board of Directors of NattoPharma has in board proceedings June 19th, 2018 granted a total of 30,000 options to Christopher Speed who started in the new position on June 18th, 2018. Mr. Speed holds no shares or options in NattoPharma ASA prior to this grant. His total holding of shares and options following this grant is 30,000 options.

The options have an exercise price equal the closing price on Oslo Axess on June 19th, 2018, which is equal to NOK 8,80.

The options granted are fully vested on December 16th, 2018 and may be exercised up to and including March 31st, 2023.

* * *

For more information, please contact:

Kjetil Ramsøy,

CEO/CFO, NattoPharma


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information is information that NattoPharma ASA (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above at 21:00 pm CET on June 19th, 2018.

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.


Documents & Links